NCT04579900 Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
| NCT ID | NCT04579900 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Laval University |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2021-02-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is now well documented that changes in gut microbiota composition accompany obesity and type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it is known that hyperglycemia during T2D induces a more permissive gut barrier allowing increased penetration of microbes and their products into the blood. An important next step is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial components to subvert the gut barrier and alter glucose control. It is hypothesized that gut microbes in the colon and other lower gut segments are key modulators of energy balance, glucose homeostasis and insulin sensitivity.
Eligibility Criteria
Inclusion Criteria: * T2DB de novo or non T2DB patients Exclusion Criteria: * oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Contact & Investigator
André Marette, PhD
PRINCIPAL INVESTIGATOR
Laval University
Frequently Asked Questions
Who can join the NCT04579900 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04579900 currently recruiting?
Yes, NCT04579900 is actively recruiting participants. Contact the research team at Genevieve.Pilon@criucpq.ulaval.ca for enrollment information.
Where is the NCT04579900 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT04579900 clinical trial?
NCT04579900 is sponsored by Laval University. The principal investigator is André Marette, PhD at Laval University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.